Lessons learnt from measures taken to prevent rabies introduction and spread into a long rabies free territory (case study of the Irkutsk Oblast) by I. V. Meltsov, A. M. Ablov, E. N. Shkolnikova, M. E. Koplik, P. A. Minchenko, T. V. Desyatova, I. D. Zarva, A. D. Botvinkin, A. Ye. Metlin

“…Measures for anti-rabies vaccination of dogs and cats were intensified. Active virological monitoring is performed on a regular basis. …”
Get full text

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC by Amr Maged Mahmoud Rasheed, Maissa E. L. Raziky, Mohammad El Sayed, Mai Mehrez, Gamal Esmat

“…Aim of the work This study aimed to ascertain the sustained virological response (SVR) to interferon-free regimens in chronic people with HCV after the successful treatment of hepatocellular carcinoma, as well as the percentage of persons who would demonstrate any radiological or laboratory alterations indicating a local or de novo recurrence of HCC. …”
Get full text

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia by V. S. Adonyeva, Ye. A. Kolodyazhnaya, A. B. Bochkarev

“…On the 4-th week of treatment rapid virologic response (RNA HCV <16 U/ml), accompanied by biochemical remission (ALT 17 U/ml, AST 19 U/ml) was achieved. …”
Get full text

Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling studyResearch in context by Caroline Klint Johannesen, David Gideonse, Richard Osei-Yeboah, Toni Lehtonen, Ombeline Jollivet, Rachel A. Cohen, Arantxa Urchueguía-Fornes, María Herrero-Silvestre, Mónica López-Lacort, Rolf Kramer, Thea K. Fischer, Terho Heikkinen, Harish Nair, Harry Campbell, Michiel van Boven, Harish Nair, Hanna Nohynek, Anne Teirlinck, Louis Bont, Peter Openshaw, Andrew Pollard, Veena Kumar, Elizabeth Begier, Jim Janimak, Jenny Hendrix, Rolf Kramer, Alejandro Orrico Sánchez, Eva Molero

“…Methods: The number of RSV hospital admissions in Denmark, England, Finland, the Netherlands, and Spain were estimated with attribution analyses, using age-specific respiratory tract infection (RTI) admissions combined with virological data, both from routinely collected healthcare data. …”
Get full text

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting by Vijay Gayam, Amrendra Kumar Mandal, Mazin Khalid, Osama Mukhtar, Arshpal Gill, Pavani Garlapati, Mowyad Khalid, Mohammed Mansour

“…Pretreatment baseline patient characteristics, treatment efficacy with the sustained virologic response at 12 weeks posttreatment (SVR12), and adverse reactions were assessed. …”
Get full text

Clinical profile and outcomes analysis of HIV infection by Ashwant Kumar, Yoganathan Chidambaram, Clement J. Dhas, Nekkanti Abilash, Murali Alagesan

“…Nearly 38% of participants showed a combination of clinical, immunological, and virological failures. Renal tubular necrosis (5%) was the most common adverse effect of HAART, while 1% developed immune reconstitution inflammatory syndrome. …”
Get full text

Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failur... by Wen-xiong Xu, Hong-liang He, Shun-wen Pan, Yuan-li Chen, Mei-ling Zhang, Shu Zhu, Zhi-liang Gao, Liang Peng, Jian-guo Li

“…The hepatic function, coagulation, and virological and immunological markers were assessed at baseline and 30, 60, 90, 180, and 360 days. …”
Get full text

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis by Jie Wang, Kaijie Qiu, Songsheng Zhou, Yichao Gan, Keting Jiang, Donghuan Wang, Haibiao Wang

“…These risks are moderated by antiviral treatments and virological responses but are exacerbated by higher HBsAg levels, anti-HBc positivity, and co-infection. …”
Get full text

Chronic glomerulonephritis of the mixed type in patient with HBV-infection (<i>Clinical case</i>) by V. S. Adonyeva, A. B. Botchkarev, O. S. Saurina

“…Treatment included entecavir 0,5 mg per day for 12 wks with normalization of transaminase levels, virologic response (DNA НВV under 50 МЕ/ML) at the 30th week, НВе seroconversion at the 42nd week of treatment.Conclusions. …”
Get full text

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2 by Naota Taura, Tatsuki Ichikawa, Hisamitsu Miyaaki, Yoshiko Kadokawa, Takuya Tsutsumi, Shotaro Tsuruta, Yuji Kato, Osami Inoue, Noboru Kinoshita, Kazuo Ohba, Hiroyuki Kato, Kazuyuki Ohata, Junichi Masuda, Keisuke Hamasaki, Hiroshi Yatsuhashi, Kazuhiko Nakao

“…Several studies have indicated that higher concentrations of serum cholesterol and LDL before treatment are important predictors of higher rates of sustained virological response (SVR). However, most of these studies involved patients infected with HCV genotype 1. …”
Get full text

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial by Anna Maria Geretti, Mathe Moeketsi, Ralph Demasi, Yvon van Delft, Perry Mohammed

“…DRV/r 800/100 mg OD in combination with ≥2 optimised NRTIs led to virological suppression <50 copies/mL in 82% of NNRTI-experienced, PI-naïve patients by week 48.…”
Get full text

Telaprevir in treatment of chronic hepatitis C: safety issues by T. M. Ignatova

“…Investigations carried out to the present time demonstrated, that addition of telaprevir to standard therapy by pegilated interferon-alpha and ribavirin increases frequency of achievement sustained virologic response in CHC patients with the 1 genotype of virus almost 2-fold. …”
Get full text

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

“…Pharmacological stimulation of thrombocytopoiesis by thrombopoietin receptors agonists (eltrombopag) prior or during AVT has allowed not only to take into account patients with initially severe thrombocytopenia as candidates for AVT, but also to carry out sufficient treatment without decrease or with lower frequency of interferon doze reduction, achieving higher rate of sustained virologic response.…”
Get full text

Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient by Giovanni Varotti, Ferdinando Dodi, Ernesto Paoletti, Andrea Bruno, Iris Fontana

“…New direct-acting antiviral agents (DAA) have dramatically changed the therapy management for HCV, showing promising results in terms of sustained virologic response. Timing for DAA therapy in HCV positive kidney waitlist patients continues to be controversial, and caution is recommended due to the potential difficult immunosuppressant dose adjustments, particularly in the early posttransplant period. …”
Get full text

Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua. by Federico Narvaez, Carlos Montenegro, Jose G Juarez, José Victor Zambrana, Karla Gonzalez, Elsa Videa, Sonia Arguello, Fanny Barrios, Sergio Ojeda, Miguel Plazaola, Nery Sanchez, Daniel Camprubí-Ferrer, Guillermina Kuan, Gabriela Paz Bailey, Eva Harris, Angel Balmaseda

“…Dengue cases were confirmed by molecular, serological, and/or virological methods, and study participants 6 months to 17 years old were followed during their hospital stay or as ambulatory patients.…”
Get full text

Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data by Yiyang Liu, Rebecca J. Fisk-Hoffman, Maitri Patel, Robert L. Cook, Mattia Prosperi

“…Of a subset of patients with HIV viral load test records, only 1 record of virologic failure (viral load > 200 copies/ml) was observed after the initiation of LAI ART. …”
Get full text

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program by V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina

“…The patients with 1b HCV genotype received treatment by combination of daclatasvir and asunaprevir 100 mg, patients with 2 and 3 HCV genotypes, and those with 1b HCV genotype after the liver transplantation received daclatasvir to sofosbuvir combination. Results. Sustained virologic response for 24 wks (SVR24) in early approach program was 89% (83 of 93) of patients with severe liver disease who urgently needed effective treatment with estimated life expectancy of less than 12 months if been untreated. …”
Get full text

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy by M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin

“…Prescription of the drug in combination to pegilated interferon and ribavirin for treatment-naive patients made possible to reduce treatment duration from 48 to 24 weeks and to increase frequency of sustained virologic response (SVR) to 87% in 1b genotypeand to 100% — in 4-th genotype. …”
Get full text

PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients by Ana Virseda-Berdices, Ana Virseda-Berdices, Óscar Brochado-Kith, Óscar Brochado-Kith, Juan Berenguer, Juan Berenguer, Juan Berenguer, Juan González-García, Juan González-García, Juan González-García, Leire Pérez-Latorre, Leire Pérez-Latorre, Leire Pérez-Latorre, Carmen Busca, Carmen Busca, Carmen Busca, Cristina Díez, Cristina Díez, Cristina Díez, Rafael Micán, Rafael Micán, Rafael Micán, Amanda Fernández-Rodríguez, Amanda Fernández-Rodríguez, María Ángeles Jiménez-Sousa, María Ángeles Jiménez-Sousa, Salvador Resino, Salvador Resino

“…We aimed to examine the association between peripheral blood mononuclear cells (PBMCs) gene expression before HCV therapy and a pronounced decrease in the liver stiffness measurement (LSM) value in HIV/HCV-coinfected patients after HCV treatment and achievement of sustained virological response (SVR).MethodsWe performed a retrospective study in 48 HIV/HCV-coinfected patients who started anti-HCV treatment with at least advanced fibrosis (LSM ≥9.5). …”
Get full text

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk by Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla, Víctor Sapena, Zoe Mariño, Sabela Lens, Ramón Vilana, Isabel Nuñez, Anna Darnell, Ernest Belmonte, Ángeles García-Criado, Alba Díaz, Marco Sanduzzi-Zamparelli, Carla Fuster, Sergio Muñoz-Martínez, Carmen Ayuso, Jordi Rimola, Alejandro Forner, Alexandre Soler, Ferran Torres, José Ríos, Jordi Bruix, Andrew M. Moon, Xavier Forns, María Reig

“…Our study investigates lifestyle changes that occur in HCV patients with Sustained Virological Response (SVR) after direct-acting antiviral (DAA) treatment. …”
Get full text